Theseus Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc. (THRX) was a U.S.-based biopharmaceutical company that traded on the NASDAQ market in the United States. Its business profile was squarely within healthcare and pharma, with a clinical-stage biotechnology model focused on the discovery, development, and eventual commercialization of transformative targeted cancer therapies. SEC filings describe Theseus as a clinical-stage company dedicated to improving outcomes for cancer patients through novel targeted therapies, which places it in the high-risk, high-upside segment of oncology biotech rather than in a diversified pharmaceutical model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1745020/000174502023000080/thrx-20230930.htm?utm_source=openai)) From an analytical perspective, Theseus was not a broad commercial drug company but a focused research-and-development biotech built around a small number of oncology programs. That business model typically depends on scientific validation, clinical milestones, regulatory progress, and external financing rather than on current product sales. As a result, the investment case was driven more by platform quality, target differentiation, and trial execution than by revenue scale or market share. In other words, Theseus represented a classic development-stage life sciences story: potentially significant value creation if the science worked, but substantial dilution and binary clinical risk along the way. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1745020/000174502023000080/thrx-20230930.htm?utm_source=openai)) The company was headquartered in Cambridge, Massachusetts, placing it in one of the most important biotech clusters in the United States. That location matters strategically: Cambridge provides access to scientific talent, research institutions, specialist advisors, and a dense network of biopharma investors and collaborators. For a company like Theseus, being embedded in that ecosystem was an important competitive advantage, especially for recruiting, partnering, and fundraising. The company’s SEC history and insider filings also show that it operated as a closely watched public biotech name, which is typical for a development-stage issuer with limited commercial visibility and a valuation anchored to pipeline execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1792204/0001209191-23-000204-index.htm?utm_source=openai)) In terms of recent major developments, the defining event was the merger with Concentra Biosciences, LLC. SEC documents show that Theseus signed a merger agreement on December 22, 2023, and that the acquisition was completed on February 14, 2024. The transaction structure included cash consideration and a contingent value right (CVR), which is a common feature in biotech dealmaking when there is uncertainty around future asset value. For investors, this is crucial context: THRX is no longer a standard operating public equity story, because the company was taken private through that transaction and its stock ceased to be an ordinary NASDAQ-listed vehicle. Any current reference to THRX is therefore mainly relevant for historical analysis, transaction review, and legacy asset tracking rather than for ongoing public-market fundamentals. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1745020/000110465924023123/tm244360d5_sc14d9a.htm?utm_source=openai))